The role of erythropoietin in the acute phase of trauma management: evidence today.
Trauma patients often present in a state of haemorrhagic shock. Blood products remain the gold standard of resuscitation, but allogeneic blood transfusions (ABTs) are associated with several risks. The stimulating effect of recombinant-erythropoietin (EPO-A) on erythropoiesis has raised interest in its administration as an alternative. The existing evidence on the early use of EPO-A in the acute phase of trauma patients management consists of only 14 publications. The level of evidence of these studies and the number of treated patients was not found to be adequate to support its generalised use, despite their favourable results. Its safety profile, the preliminary proofs of its efficacy, and the additional cyto-protective properties of EPO-A strongly encourage further controlled studies assessing its use in the acute setting of initial trauma management.
Kanakaris
N K
NK
Academic Department of Trauma & Orthopaedics, Leeds Teaching Hospitals, Leeds, UK.
Petsatodis
G
G
Chalidis
B
B
Manidakis
N
N
Kontakis
G
G
Giannoudis
P V
PV
D000058:Accidental Falls; D000063:Accidents, Traffic; D004632:Emergency Medical Services / Q000379:methods*; D004921:Erythropoietin / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D033221:Jehovah's Witnesses; D011994:Recombinant Proteins; D012771:Shock, Hemorrhagic / Q000188:drug therapy; D013268:Stimulation, Chemical; D014947:Wounds and Injuries / Q000628:therapy*
D011994:Recombinant Proteins; D004921:Erythropoietin